Yun-Ai Su1, Jing-Yu Lin1, Qi Liu1, Xiao-Zhen Lv1, Gang Wang2, Jing Wei3, Gang Zhu4, Qiao-Ling Chen5, Hong-Jun Tian6, Ke-Rang Zhang7, Xue-Yi Wang8, Nan Zhang9, Ying Wang10, Ebrahim Haroon11, Xin Yu12, Tian-Mei Si13. 1. Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China. 2. Beijing Anding Hospital, Capital Medical University, Beijing, China. 3. Peking Union Medical College (PUMC), Beijing, China. 4. The First Hospital of China Medical University, Shenyang, China. 5. Dalian Seventh People's Hospital, Dalian, China. 6. Tianjin Anding Hospital, Tianjin, China. 7. Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China. 8. The First Hospital of Hebei Medical University, Shijiazhuang, China. 9. Tianjin Medical University General Hospital, Tianjin, China. 10. The 984th Hospital of PLA, Beijing, China. 11. Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA. 12. Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China. Electronic address: yuxin@bjmu.edu.cn. 13. Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China. Electronic address: si.tian-mei@163.com.
Abstract
BACKGROUND: Patients with major depressive disorder (MDD) are at high risk for suicide. As the worst outcome of MDD and common self-concealment in patients with suicide risk, studies of biomarkers may provide useful tools for suicide prevention and treatment. METHODS: This study recruited 168 patients with MDD from the Objective Diagnostic Markers and Personalized Intervention in MDD patients (ODMPIM), including 50 patients with suicide risk. Based on previous evidence and hypothesis, 23 targeted serum biomarkers involving immune-inflammation, neurotrophins, hypothalamic-pituitary-adrenal (HPA) axis and metabolism, were measured. We used path analysis and principal components analysis (PCA) to clarify the associations among serum biomarkers, childhood adversities, adulthood life events, severity of depression and suicide risk. RESULTS: We identified that patients with suicide risk had a higher level of inflammatory markers in serum than patients without suicide risk (P < 0.001), especially chemokine (C-X-C motif) ligand 1 (CXCL-1). After using the Bonferroni correction, there were no differences in biomarkers related to neurotrophins, HPA-axis and metabolism. In addition, a higher proportion of patients with suicide risk had adulthood adversity (assessed by Life Events Scale) (P = 0.003). Intriguingly, path analysis demonstrated that the association between adulthood adversity and suicide risk mainly depended on severity of depression and inflammatory index. CONCLUSION: This study highlights the possible role of inflammation involved in suicide risk of MDD patients. Inflammatory markers have the potential for early identification and then reducing suicidal behaviors or becoming novel treatment targets in suicide risk management.
BACKGROUND:Patients with major depressive disorder (MDD) are at high risk for suicide. As the worst outcome of MDD and common self-concealment in patients with suicide risk, studies of biomarkers may provide useful tools for suicide prevention and treatment. METHODS: This study recruited 168 patients with MDD from the Objective Diagnostic Markers and Personalized Intervention in MDDpatients (ODMPIM), including 50 patients with suicide risk. Based on previous evidence and hypothesis, 23 targeted serum biomarkers involving immune-inflammation, neurotrophins, hypothalamic-pituitary-adrenal (HPA) axis and metabolism, were measured. We used path analysis and principal components analysis (PCA) to clarify the associations among serum biomarkers, childhood adversities, adulthood life events, severity of depression and suicide risk. RESULTS: We identified that patients with suicide risk had a higher level of inflammatory markers in serum than patients without suicide risk (P < 0.001), especially chemokine (C-X-C motif) ligand 1 (CXCL-1). After using the Bonferroni correction, there were no differences in biomarkers related to neurotrophins, HPA-axis and metabolism. In addition, a higher proportion of patients with suicide risk had adulthood adversity (assessed by Life Events Scale) (P = 0.003). Intriguingly, path analysis demonstrated that the association between adulthood adversity and suicide risk mainly depended on severity of depression and inflammatory index. CONCLUSION: This study highlights the possible role of inflammation involved in suicide risk of MDDpatients. Inflammatory markers have the potential for early identification and then reducing suicidal behaviors or becoming novel treatment targets in suicide risk management.
Authors: Jenessa N Johnston; Darcy Campbell; Hector J Caruncho; Ioline D Henter; Elizabeth D Ballard; Carlos A Zarate Journal: Int J Neuropsychopharmacol Date: 2022-03-17 Impact factor: 5.176